Abstract
Summary
Bacterial Vaginosis Medicine is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.
LPI (LP Information)' newest research report, the “Bacterial Vaginosis Medicine Industry Forecast” looks at past sales and reviews total world Bacterial Vaginosis Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected Bacterial Vaginosis Medicine sales for 2023 through 2029. With Bacterial Vaginosis Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bacterial Vaginosis Medicine industry.
This Insight Report provides a comprehensive analysis of the global Bacterial Vaginosis Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bacterial Vaginosis Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bacterial Vaginosis Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bacterial Vaginosis Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bacterial Vaginosis Medicine.
The global Bacterial Vaginosis Medicine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Bacterial Vaginosis Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Bacterial Vaginosis Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Bacterial Vaginosis Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Bacterial Vaginosis Medicine players cover Bayer, Pfizer, Sanofi, Piramal, Abbott, Galderma, Mission, Alkem and Xiuzheng, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Bacterial Vaginosis Medicine market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Rx
OTC
Segmentation by application
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Pfizer
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge
LPI (LP Information)' newest research report, the “Bacterial Vaginosis Medicine Industry Forecast” looks at past sales and reviews total world Bacterial Vaginosis Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected Bacterial Vaginosis Medicine sales for 2023 through 2029. With Bacterial Vaginosis Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bacterial Vaginosis Medicine industry.
This Insight Report provides a comprehensive analysis of the global Bacterial Vaginosis Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bacterial Vaginosis Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bacterial Vaginosis Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bacterial Vaginosis Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bacterial Vaginosis Medicine.
The global Bacterial Vaginosis Medicine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Bacterial Vaginosis Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Bacterial Vaginosis Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Bacterial Vaginosis Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Bacterial Vaginosis Medicine players cover Bayer, Pfizer, Sanofi, Piramal, Abbott, Galderma, Mission, Alkem and Xiuzheng, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Bacterial Vaginosis Medicine market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Rx
OTC
Segmentation by application
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Pfizer
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Bacterial Vaginosis Medicine Market Size 2018-2029
2.1.2 Bacterial Vaginosis Medicine Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Bacterial Vaginosis Medicine Segment by Type
2.2.1 Rx
2.2.2 OTC
2.3 Bacterial Vaginosis Medicine Market Size by Type
2.3.1 Bacterial Vaginosis Medicine Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Bacterial Vaginosis Medicine Market Size Market Share by Type (2018-2023)
2.4 Bacterial Vaginosis Medicine Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Bacterial Vaginosis Medicine Market Size by Application
2.5.1 Bacterial Vaginosis Medicine Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Bacterial Vaginosis Medicine Market Size Market Share by Application (2018-2023)
3 Bacterial Vaginosis Medicine Market Size by Player
3.1 Bacterial Vaginosis Medicine Market Size Market Share by Players
3.1.1 Global Bacterial Vaginosis Medicine Revenue by Players (2018-2023)
3.1.2 Global Bacterial Vaginosis Medicine Revenue Market Share by Players (2018-2023)
3.2 Global Bacterial Vaginosis Medicine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Bacterial Vaginosis Medicine by Regions
4.1 Bacterial Vaginosis Medicine Market Size by Regions (2018-2023)
4.2 Americas Bacterial Vaginosis Medicine Market Size Growth (2018-2023)
4.3 APAC Bacterial Vaginosis Medicine Market Size Growth (2018-2023)
4.4 Europe Bacterial Vaginosis Medicine Market Size Growth (2018-2023)
4.5 Middle East & Africa Bacterial Vaginosis Medicine Market Size Growth (2018-2023)
5 Americas
5.1 Americas Bacterial Vaginosis Medicine Market Size by Country (2018-2023)
5.2 Americas Bacterial Vaginosis Medicine Market Size by Type (2018-2023)
5.3 Americas Bacterial Vaginosis Medicine Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bacterial Vaginosis Medicine Market Size by Region (2018-2023)
6.2 APAC Bacterial Vaginosis Medicine Market Size by Type (2018-2023)
6.3 APAC Bacterial Vaginosis Medicine Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Bacterial Vaginosis Medicine by Country (2018-2023)
7.2 Europe Bacterial Vaginosis Medicine Market Size by Type (2018-2023)
7.3 Europe Bacterial Vaginosis Medicine Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Bacterial Vaginosis Medicine by Region (2018-2023)
8.2 Middle East & Africa Bacterial Vaginosis Medicine Market Size by Type (2018-2023)
8.3 Middle East & Africa Bacterial Vaginosis Medicine Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Bacterial Vaginosis Medicine Market Forecast
10.1 Global Bacterial Vaginosis Medicine Forecast by Regions (2024-2029)
10.1.1 Global Bacterial Vaginosis Medicine Forecast by Regions (2024-2029)
10.1.2 Americas Bacterial Vaginosis Medicine Forecast
10.1.3 APAC Bacterial Vaginosis Medicine Forecast
10.1.4 Europe Bacterial Vaginosis Medicine Forecast
10.1.5 Middle East & Africa Bacterial Vaginosis Medicine Forecast
10.2 Americas Bacterial Vaginosis Medicine Forecast by Country (2024-2029)
10.2.1 United States Bacterial Vaginosis Medicine Market Forecast
10.2.2 Canada Bacterial Vaginosis Medicine Market Forecast
10.2.3 Mexico Bacterial Vaginosis Medicine Market Forecast
10.2.4 Brazil Bacterial Vaginosis Medicine Market Forecast
10.3 APAC Bacterial Vaginosis Medicine Forecast by Region (2024-2029)
10.3.1 China Bacterial Vaginosis Medicine Market Forecast
10.3.2 Japan Bacterial Vaginosis Medicine Market Forecast
10.3.3 Korea Bacterial Vaginosis Medicine Market Forecast
10.3.4 Southeast Asia Bacterial Vaginosis Medicine Market Forecast
10.3.5 India Bacterial Vaginosis Medicine Market Forecast
10.3.6 Australia Bacterial Vaginosis Medicine Market Forecast
10.4 Europe Bacterial Vaginosis Medicine Forecast by Country (2024-2029)
10.4.1 Germany Bacterial Vaginosis Medicine Market Forecast
10.4.2 France Bacterial Vaginosis Medicine Market Forecast
10.4.3 UK Bacterial Vaginosis Medicine Market Forecast
10.4.4 Italy Bacterial Vaginosis Medicine Market Forecast
10.4.5 Russia Bacterial Vaginosis Medicine Market Forecast
10.5 Middle East & Africa Bacterial Vaginosis Medicine Forecast by Region (2024-2029)
10.5.1 Egypt Bacterial Vaginosis Medicine Market Forecast
10.5.2 South Africa Bacterial Vaginosis Medicine Market Forecast
10.5.3 Israel Bacterial Vaginosis Medicine Market Forecast
10.5.4 Turkey Bacterial Vaginosis Medicine Market Forecast
10.5.5 GCC Countries Bacterial Vaginosis Medicine Market Forecast
10.6 Global Bacterial Vaginosis Medicine Forecast by Type (2024-2029)
10.7 Global Bacterial Vaginosis Medicine Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Bacterial Vaginosis Medicine Product Offered
11.1.3 Bayer Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Bacterial Vaginosis Medicine Product Offered
11.2.3 Pfizer Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Bacterial Vaginosis Medicine Product Offered
11.3.3 Sanofi Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Sanofi Main Business Overview
11.3.5 Sanofi Latest Developments
11.4 Piramal
11.4.1 Piramal Company Information
11.4.2 Piramal Bacterial Vaginosis Medicine Product Offered
11.4.3 Piramal Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Piramal Main Business Overview
11.4.5 Piramal Latest Developments
11.5 Abbott
11.5.1 Abbott Company Information
11.5.2 Abbott Bacterial Vaginosis Medicine Product Offered
11.5.3 Abbott Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Abbott Main Business Overview
11.5.5 Abbott Latest Developments
11.6 Galderma
11.6.1 Galderma Company Information
11.6.2 Galderma Bacterial Vaginosis Medicine Product Offered
11.6.3 Galderma Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Galderma Main Business Overview
11.6.5 Galderma Latest Developments
11.7 Mission
11.7.1 Mission Company Information
11.7.2 Mission Bacterial Vaginosis Medicine Product Offered
11.7.3 Mission Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Mission Main Business Overview
11.7.5 Mission Latest Developments
11.8 Alkem
11.8.1 Alkem Company Information
11.8.2 Alkem Bacterial Vaginosis Medicine Product Offered
11.8.3 Alkem Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Alkem Main Business Overview
11.8.5 Alkem Latest Developments
11.9 Xiuzheng
11.9.1 Xiuzheng Company Information
11.9.2 Xiuzheng Bacterial Vaginosis Medicine Product Offered
11.9.3 Xiuzheng Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Xiuzheng Main Business Overview
11.9.5 Xiuzheng Latest Developments
11.10 Teva
11.10.1 Teva Company Information
11.10.2 Teva Bacterial Vaginosis Medicine Product Offered
11.10.3 Teva Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Teva Main Business Overview
11.10.5 Teva Latest Developments
11.11 Perrigo
11.11.1 Perrigo Company Information
11.11.2 Perrigo Bacterial Vaginosis Medicine Product Offered
11.11.3 Perrigo Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Perrigo Main Business Overview
11.11.5 Perrigo Latest Developments
11.12 West-Ward
11.12.1 West-Ward Company Information
11.12.2 West-Ward Bacterial Vaginosis Medicine Product Offered
11.12.3 West-Ward Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 West-Ward Main Business Overview
11.12.5 West-Ward Latest Developments
11.13 HPGC
11.13.1 HPGC Company Information
11.13.2 HPGC Bacterial Vaginosis Medicine Product Offered
11.13.3 HPGC Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 HPGC Main Business Overview
11.13.5 HPGC Latest Developments
11.14 Yunnan Baiyao
11.14.1 Yunnan Baiyao Company Information
11.14.2 Yunnan Baiyao Bacterial Vaginosis Medicine Product Offered
11.14.3 Yunnan Baiyao Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Yunnan Baiyao Main Business Overview
11.14.5 Yunnan Baiyao Latest Developments
11.15 Starpharma
11.15.1 Starpharma Company Information
11.15.2 Starpharma Bacterial Vaginosis Medicine Product Offered
11.15.3 Starpharma Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Starpharma Main Business Overview
11.15.5 Starpharma Latest Developments
11.16 Novel
11.16.1 Novel Company Information
11.16.2 Novel Bacterial Vaginosis Medicine Product Offered
11.16.3 Novel Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Novel Main Business Overview
11.16.5 Novel Latest Developments
11.17 Edenvridge
11.17.1 Edenvridge Company Information
11.17.2 Edenvridge Bacterial Vaginosis Medicine Product Offered
11.17.3 Edenvridge Bacterial Vaginosis Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Edenvridge Main Business Overview
11.17.5 Edenvridge Latest Developments
12 Research Findings and Conclusion